Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL5182658 | 1.00 | CYP2D6 (0.46) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL14935915 | 0.98 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL2939473 | 0.98 | CYP2D6 (0.48) | CYP2D6SRCDPP4LMNAMAPK1 | |
| Methane SCHEMBL20292606 | 0.84 | TDP1 (0.43) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL28688103 | 0.82 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL3112337 | 0.82 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| SCHEMBL189878 | 0.82 | TDP1 (0.44) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| Iodide SCHEMBL27294834 | 0.80 | TDP1 (0.43) | CYP2D6SRCLMNASLC1A2SLC1A3 | |
| Methane SCHEMBL29238636 | 0.78 | DPP4 (0.50) | CYP2D6SRCDPP4LMNAMAPK1 | |
| SCHEMBL43670 | 0.76 | DPP4 (0.52) | CYP2D6SRCDPP4LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1366025-B1 | AGONISTS OF BETA-ADRENORECEPTORS | GLAXO GROUP LTD (GB) | 2007-06-27 | — | — | EP | disclosed |
| US-7144908-B2 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20040242890-A1 | Agonists of beta-adrenoceptors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1366025-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002070490-A1 | AGONISTS OF BETA-ADRENOCEPTORS | GLAXO GROUP LIMITED (GB) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242890-A1 | Agonists of beta-adrenoceptors | ADRB1, ADRB2, ADRA1A | CYP2D6 696/4885SRC 3846/4885DPP4 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.